BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16814560)

  • 1. The pharmacoeconomic impact of amlodipine use on coronary artery disease.
    De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Aug; 54(2):158-63. PubMed ID: 16814560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA.
    Rossetti F; De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Mar; 53(3):197-201. PubMed ID: 16406672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden.
    Doyle JJ; McGuire A; Arocho R; Arikian S; Casciano J; Svangren P; Casciano R; Kim R; Kugel H
    Int J Clin Pract; 2002 Mar; 56(2):76-81. PubMed ID: 11926709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic benefits of amlodipine treatment in patients with coronary artery disease.
    Casciano R; Doyle JJ; Chen J; Arikian S; Casciano J; Kugel H; Arocho R
    Pharmacoeconomics; 2002; 20(8):553-63. PubMed ID: 12109920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure: findings from the CAMELOT economic substudy.
    Menzin J; Boulanger L; Tang S; Thakker K; Nissen SE
    Appl Health Econ Health Policy; 2008; 6(2-3):157-62. PubMed ID: 19231908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine: a pharmacoeconomic review.
    de Portu S; Mantovani LG
    J Med Econ; 2009 Mar; 12(1):60-8. PubMed ID: 19450066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study.
    O'Connor CM; Radensky PW; Unger AN; Martin BC
    Clin Ther; 1999 Jul; 21(7):1254-65. PubMed ID: 10463522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute coronary syndromes in Europe: 1-year costs and outcomes.
    Taylor MJ; Scuffham PA; McCollam PL; Newby DE
    Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic efficiency of amlodipine in the treatment of coronary atherosclerosis--an analysis based on the PREVENT study.
    Cathomas G; Erne P; Schwenkglenks M; Szucs TD
    Cardiovasc Drugs Ther; 2002 Jan; 16(1):61-6. PubMed ID: 12085980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study.
    Ma W; Sun N; Duan C; Zhao L; Hua Q; Sun Y; Dang A; Gao P; Qu P; Cui W; Zhao L; Dong Y; Cui L; Qi X; Jiang Y; Xie J; Li J; Wu G; Du X; Huo Y; Chen P;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):41-50. PubMed ID: 32915349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada.
    Thaulow E; Jorgensen B; Doyle JJ; Casciano R; Casciano J; Kopp Z; Arikian S; Kim R
    Int J Cardiol; 2002 Jul; 84(1):23-30; discussion 30-2. PubMed ID: 12104059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
    Mancini GB
    Can J Cardiol; 2000 Jul; 16 Suppl D():5D-7D. PubMed ID: 10932029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials.
    Brener SJ; Ivanc TB; Poliszczuk R; Chen M; Tuzcu EM; Hu T; Frid DJ; Nissen SE
    Am Heart J; 2006 Dec; 152(6):1059-63. PubMed ID: 17161053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.